---
schema_version: "secwatch.filing_event.v1"
accession: "0001326110-26-000077"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2026-08-04T11:36:13+00:00"
generated_at: "2026-08-04T11:40:33.667860+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth

## Summary
- Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.
- Cash and marketable securities $357.4M as of June 30, 2026; adjusted net loss improved to $81.0M from $89.9M YoY.
- FDA accepted sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA Jan 6, 2027.
- UAE granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC.
- Exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG in NMIBC.

## SEC filing metadata
- accession: 0001326110-26-000077
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2026-08-04T11:36:13+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/0001326110-26-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000132611026000077/ibrx-20260804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326110-26-000077
- JSON: https://secwatch.observer/filing/0001326110-26-000077.json
- Plain text: https://secwatch.observer/filing/0001326110-26-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.